Brief: Synthaverse Receives Marketing Authorization For Onko BCG Drug In The Netherlands
13/11/2025 15:48
Nov 13 (Reuters) - Synthaverse SA SVEP.WA: RECEIVES MARKETING AUTHORIZATION FOR ONKO BCG DRUG IN THE NETHERLANDS Source text: ID:nEM1y5H71a Further company coverage: SVEP.WA (Reporting by Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Synthaverse SA
See all newsBrief: Synthaverse EGM To Vote On Share Capital Increase Via Series X Share Issue
Brief: Synthaverse Gets 45 Mln Zloty Loan From Polish Agency For Enterprise Development For Debt Refinancing
Brief: Synthaverse Receives Registration Certificate For Onko BCG Product In Paraguay Under Partnership With Blau
Brief: Synthaverse H1 Net Loss At 6.4 Mln Zlotys
Brief: Synthaverse Gets Poland's GIF Decision Extending Manufacturing For New Immunological Products Facility